Drugs are screened across multiple established cell line models for each disease. We have tested 140 unique, individual agents so far, at multiple concentrations. Selected agents are either FDA-approved, clinically promising, or experimentally interesting. The drug concentrations we test are determined based on several factors, most important being published pharmacokinetics. We make the best possible effort to ensure drugs are tested at clinically achievable and physiologically relevant conditions. From these individual agents, we have screened over 250 combinations of agents at an average of 25 different concentrations for each combination. In other words, we have obtained data for over 6,000 different two-drug regimens altogether across these 5 diseases. To do this, we have teamed up with the translational research core at Moffitt Cancer Center in Tampa, FL. Pooling our resources together, we employ 3 liquid handling robots, 2 plate readers, multiple sterile hoods, and all the basic tools necessary to generate high quality, high confidence data. In addition to the important task of finding promising new treatment regimens for these diseases, we use cutting-edge technology to investigate the molecular biological mechanisms underlying these cancers. Combining our library of screening data with our biochemical studies allows us to better understand each individual disease so that we can focus in on the chemotherapeutics that are most likely to provide good results in the clinic. Since 2013, we have published 4 original research articles and currently have 2 more in the submission process. We have shared our data with the scientific community at the American Association of Cancer Researchers (AACR) annual conference every year starting in 2014. We have also presented our data at conferences and symposia hosted by the Children’s Tumor Foundation (CTF), Connective Tissue Oncology Society (CTOS), John’s Hopkins All Children’s Hospital (JHACH), Cancer Prevention & Research Institute of Texas (CPRIT), and others.